Chiesi Farmaceutici

Chiesi's international growth continues

Retrieved on: 
Mercoledì, Aprile 5, 2023
China Biologic Products, Benefit corporation, B Lab, Respiratory disease, European Patent Office, EPO, EBITDA, Sustainability, Investment, European Patent Convention, Growth, B Corporation (certification), Environment, Fine chemical, Pharmaceutical industry, Chiesi Farmaceutici

It has a solid positive net financial position of €1,390 million, €342 million more than previous year.

Key Points: 
  • It has a solid positive net financial position of €1,390 million, €342 million more than previous year.
  • A commitment that I share, together with the Chiesi family, and that will drive us into the next stages of international growth."
  • Research growth is mainly driven by partnerships and collaborations (Allinaire Therapeutics, Aptar Digital health, Kaia Health) and acquisitions (Amryt).
  • In July 2022, Chiesi – a Benefit Corporation in Italy (Società Benefit), the United States and France (Société à Mission) – achieved B Corp recertification by international non-profit organisation B Lab.

Chiesi USA donates more than $830,000 to local communities and nonprofits in 2022

Retrieved on: 
Martedì, Marzo 28, 2023
American Heart Association, The Salvation Army, Cystic fibrosis, Durham Bulls, Social, Hospital, Customer, Enterprise Community Partners, Nursing care plan, Health, Environment, Neonatology, Durham Bulls Athletic Park, Ronald, Research, Organization, Cystic Fibrosis Foundation, Rare, Food security, American Society of Health-System Pharmacists, Volunteering, Senior, Bulls, CITC, National Organization for Rare Disorders, CSR, DE, Triangle, Superhero, ASHP, CME, Partnership, Boomer Esiason, McDonald House, Quality of life, Woman, Pharmacy, Student, Community, U.S. Army Community Relations, Society, Tourism, Pharmaceutical industry, Management, Hope, Chiesi Farmaceutici

(key-A-zee), a Cary-based specialty pharmaceutical company, contributed more than $830,000 in 2022 through its Chiesi in the Community (CITC) corporate social responsibility (CSR) program.

Key Points: 
  • (key-A-zee), a Cary-based specialty pharmaceutical company, contributed more than $830,000 in 2022 through its Chiesi in the Community (CITC) corporate social responsibility (CSR) program.
  • As an employee-led program, close to 200 Chiesi employees supported 65 unique charitable organizations with 769 hours of time or donations in 2022.
  • “For Chiesi USA and our employees, the Triangle isn’t just a place of business.
  • Recognized as a Certified B CorporationTM in 2019, Chiesi demonstrates its commitment to meeting high standards of social and environmental performance, transparency, and accountability.

AMYT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Amryt Pharma Plc Is Fair to Shareholders

Retrieved on: 
Lunedì, Febbraio 27, 2023
Class Action Lawsuit, Professional Services, Legal, Advertising, Sale, Contingent value rights, ADS, Fraud, Security (finance), Chiesi Farmaceutici

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Amryt Pharma Plc (NASDAQ: AMYT) to Chiesi Farmaceutici S.p.A. is fair to Amryt shareholders.

Key Points: 
  • Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Amryt Pharma Plc (NASDAQ: AMYT) to Chiesi Farmaceutici S.p.A. is fair to Amryt shareholders.
  • On behalf of Amryt shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.
  • Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MAXR, AMYT, ALR

Retrieved on: 
Domenica, Febbraio 26, 2023
Advertising, NYSE, Maxar Technologies, Contingent value rights, Sale, ADS, Advent International, Fraud, Security (finance), Chiesi Farmaceutici

If you are a Maxar shareholder, click here to learn more about your legal rights and options .

Key Points: 
  • If you are a Maxar shareholder, click here to learn more about your legal rights and options .
  • If you are an Amryt shareholder, click here to learn more about your rights and options .
  • Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected] .
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

Protalix BioTherapeutics to Participate in the 19th Annual WORLDSymposium™ 2023

Retrieved on: 
Martedì, Febbraio 21, 2023
NYSE, TASE, Protalix BioTherapeutics, PEGylation, Fabry disease, Abstract, Hilton Orlando Lake Buena Vista, Vaccine, Chiesi Farmaceutici

CARMIEL, Israel, Feb. 21, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today announced that it will participating in the 19th Annual WORLDSymposium™ 2023, taking place February 22–26, 2023 at the Hilton Orlando in Orlando, Florida.

Key Points: 
  • CARMIEL, Israel, Feb. 21, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today announced that it will participating in the 19th Annual WORLDSymposium™ 2023, taking place February 22–26, 2023 at the Hilton Orlando in Orlando, Florida.
  • The Company will be hosting an informational booth at the symposium.
  • PRX–102 is a purposefully-designed, long-acting recombinant, PEGylated, cross–linked α–galactosidase–A investigational product candidate under development for the potential treatment of Fabry disease.
  • The Company will make Chiesi's PRX–102 presentations and related abstracts on its website under the Presentation tab in the Investors section: https://protalixbiotherapeutics.gcs-web.com/presentations .

Chiesi Global Rare Diseases Announces FDA Approval of Lamzede®(velmanase alfa-tycv) for Alpha-Mannosidosis

Retrieved on: 
Giovedì, Febbraio 16, 2023
Caregiver, Conjunctivitis, Enzyme replacement therapy, European Commission, Disorder, Sugar, National Healthcare Group, Muscle weakness, Rash, Antipyretic, Medicine, Patient, Speech, Tissue, Erythema, AM, Hives, Civil service commission, Tremor, Vomiting, Birth, Incidence, Alpha-mannosidosis, Food, Oligosaccharide, Alpha-Mannosidase, Anaphylaxis, Cough, Common, International Society, Cyanosis, Headache, Chills, Hearing, Disease, FDA, Hypotension, IAR, Prevalence, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Cardiopulmonary resuscitation, Arthralgia, Glycogen storage disease, Hearing loss, Pharmaceutical industry, Nursing, Birth control, Fever, Chiesi Farmaceutici, Velmanase alfa

BOSTON, Feb. 16, 2023 /PRNewswire/ -- Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), announced today that the U.S. Food and Drug Administration (FDA) has approved Lamzede® (velmanase alfa-tycv) for the treatment of non-central nervous system manifestations of alpha-mannosidosis (AM) in adult and pediatric patients. AM is an ultra-rare, progressive lysosomal storage disorder caused by deficiency in the enzyme α-mannosidase.

Key Points: 
  • "Today's approval of Lamzede represents a major milestone for people living with alpha-mannosidosis.
  • Lamzede is the first and only enzyme replacement therapy approved for alpha-mannosidosis in the United States, an achievement based on years of clinical development, as well as the dedication of our employees, clinicians, patients and their families," said Giacomo Chiesi, head of Chiesi Global Rare Diseases.
  • The prevalence of AM is approximately one in every 500,000 to one in every 1,000,000 babies born worldwide.
  • For females of reproductive potential, verify that the patient is not pregnant prior to initiating treatment with Lamzede.

Chiesi appoints Giuseppe Accogli as new Group CEO

Retrieved on: 
Lunedì, Gennaio 30, 2023
Head, Corporate Affairs, Health, Environment, Growth, Corporate development, Baxter, Trust, R, Medtronic, Marketing, Management, Chiesi Farmaceutici

"As CEO, I strive to enable our leaders, people and partners to achieve even greater success in fulfilling the commitment to be a sustainable force for good in the biopharmaceutical industry" says Giuseppe Accogli

Key Points: 
  • "As CEO, I strive to enable our leaders, people and partners to achieve even greater success in fulfilling the commitment to be a sustainable force for good in the biopharmaceutical industry" says Giuseppe Accogli
    PARMA, Italy, Jan. 30, 2023 /PRNewswire/ -- Chiesi, the international research-focused biopharmaceutical Group, is pleased to announce Giuseppe Accogli as new Group CEO.
  • Giuseppe Accogli is a successful Executive Leader with 25 years of international experience in the med-tech sector of reputed and complex companies such as Baxter and Medtronic.
  • The combination of his experience, values, and drive makes him an ideal fit for Chiesi Group.
  • "We are thrilled to have Giuseppe in the CEO role," Alberto Chiesi, President of Chiesi Group, says.

Chiesi appoints Giuseppe Accogli as new Group CEO

Retrieved on: 
Lunedì, Gennaio 30, 2023
Head, Corporate Affairs, Health, Environment, Growth, Corporate development, Baxter, Trust, R, Medtronic, Marketing, Management, Chiesi Farmaceutici

"As CEO, I strive to enable our leaders, people and partners to achieve even greater success in fulfilling the commitment to be a sustainable force for good in the biopharmaceutical industry" says Giuseppe Accogli

Key Points: 
  • "As CEO, I strive to enable our leaders, people and partners to achieve even greater success in fulfilling the commitment to be a sustainable force for good in the biopharmaceutical industry" says Giuseppe Accogli
    PARMA, Italy, Jan. 30, 2023 /PRNewswire/ -- Chiesi, the international research-focused biopharmaceutical Group, is pleased to announce Giuseppe Accogli as new Group CEO.
  • Giuseppe Accogli is a successful Executive Leader with 25 years of international experience in the med-tech sector of reputed and complex companies such as Baxter and Medtronic.
  • The combination of his experience, values, and drive makes him an ideal fit for Chiesi Group.
  • "We are thrilled to have Giuseppe in the CEO role," Alberto Chiesi, President of Chiesi Group, says.

Global Chronic Obstructive Pulmonary Disease Drugs Market to Grow by $66.54 Billion During 2023-2027 - ResearchAndMarkets.com

Retrieved on: 
Mercoledì, Gennaio 11, 2023
General Health, Pharmaceutical, Health, Chronic obstructive pulmonary disease, Novartis, Vertex Pharmaceuticals, Spondyloarthropathy, Lupin Limited, Smoking, AstraZeneca, Chiesi Farmaceutici, A.D. Bedell Wholesale Co., Inc. v. Philip Morris Inc., Research, Viatris, Philip Morris International, Dendrite International, Inc. v. Doe No. 3, GlaxoSmithKline

This study identifies the expanding research in curative approaches as one of the prime reasons driving the chronic obstructive pulmonary disease drugs market growth during the next few years.

Key Points: 
  • This study identifies the expanding research in curative approaches as one of the prime reasons driving the chronic obstructive pulmonary disease drugs market growth during the next few years.
  • Also, advances in drug delivery devices and the growing use of e-cigarettes and other products for people to quit smoking will lead to sizable demand in the market.
  • The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters.
  • The publisher's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HZN, AMYT, CINC

Retrieved on: 
Domenica, Gennaio 15, 2023
ADS, Contingent value rights, Advertising, NYSE, AstraZeneca, Sale, Collection, Fraud, Security (finance), Chiesi Farmaceutici

If you are a Horizon Global shareholder, click here to learn more about your legal rights and options .

Key Points: 
  • If you are a Horizon Global shareholder, click here to learn more about your legal rights and options .
  • If you are an Amryt shareholder, click here to learn more about your rights and options .
  • Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected] .
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.